FDA nod is just the first hurdle for Moderna’s potential blockbuster flu vax

Strain selection timing and mRNA skepticism could limit the impact of Moderna’s game-changing mRNA flu shot.

By Alexandra Pecci • Aug. 17, 2026

BMS builds big in Texas; Regeneron backs would-be rival

BMS reveals plans for a new manufacturing hub in Houston, and Regeneron invests in startup developing a Dupixent competitor.

By PharmaVoice Staff • Aug. 14, 2026

Explore the Trendline➔

Artificial intelligence & machine learning

After years of excited buzz around the potential of artificial intelligence and machine learning, pharma has begun to realize the true implications and potential value of these technologies.

By PharmaVoice staff

Biotech initiatives pick up as more regions race to become hubs

New government funding from Pennsylvania to Kansas City is strengthening biotech hubs — but experts say money alone won’t determine where pharma builds next.

By Alexandra Pecci • Aug. 13, 2026

Trump has another tariff plan to reshore generic drug production. Will it work?

The president’s most recent tariff proposal gives pharma more time to transition its global supply chain and reshore generic drug production.

By Kelly Bilodeau • Aug. 3, 2026

How Telix landed a $2.1 billion radiopharma deal with Regeneron

Regeneron tapped the Aussie biotech to enter the radiopharma market with a multi-pronged agreement. 

By Alexandra Pecci • July 30, 2026

Beyond Boston: Unlikely cities stake biotech claims

As Greater Boston’s biotech industry sheds jobs, three unlikely regions are showing promise as up-and-coming hubs.

By Alexandra Pecci • July 6, 2026

Does US manufacturing give drugmakers a speed edge?

Aquestive’s fast response to an FDA rejection reveals why some drugmakers are betting on domestic operations despite pricing pressures and overseas supply dependencies.

By Kelly Bilodeau • June 23, 2026

Backed by Sanofi and Roche, Orano Med chases radiopharma leadership

Orano Med’s industrial platform offers “unlimited” and unique access to the cancer-fighting alpha emitter lead-212.

By Alexandra Pecci • June 22, 2026

India’s pharma industry is going global. But can it catch up to China?

A record  Sun Pharma acquisition signals global ambitions. But infrastructure, capital and policy gaps could stand in the way of India becoming an R&D powerhouse.

By Kelly Bilodeau • May 13, 2026

Tariffs are back. What does it mean now for pharma?

While the Trump administration has again levied large new tariffs, drugmakers willing to make deals could gain some relief.

By Kelly Bilodeau • April 6, 2026

How Trump’s war in Iran is scrambling pharma’s shipping options

A blockade at one of the world’s largest shipping lanes could shape the way pharma companies think about manufacturing and distribution.

By Michael Gibney • April 2, 2026

Gilead could potentially end HIV. But will it be able to?

After launching a PrEP medication that was 100% effective in clinical trials, the company is facing a complex global rollout and leveraging its network of partners for help.

By Meagan Parrish • March 20, 2026

Lilly’s manufacturing bet; hints of a biotech revival

Lilly is investing billions more into Chinese manufacturing — and other topics on our radar this week.

By PharmaVoice Staff • March 20, 2026

Operating a new standard for life-saving pharmaceutical logistics

Lowering risk and tightening temperature control for today’s complex pharmaceutical logistics.

Feb. 23, 2026

Texas, N. Carolina, Ohio, Pennsylvania — where pharma manufacturing investments have surged

Pledged projects have landed in a handful of hotspots while giving rise to potential new hubs across the U.S.

By Alexandra Pecci • Jan. 20, 2026

Redefining CAR-T speed and strength with DAR-T™: A conversation with Nicholas Kirian

In this Q&A discover how DAR-T, a CAR-T platform, addresses challenges in cell therapy manufacturing.

By Nicholas Kirian • Dec. 1, 2025

4 takeaways from pharma’s manufacturing boom

As pharma’s U.S. facility investments top $370 billion over the next five years, there are a few things to keep in mind, according to construction experts.

By Alexandra Pecci • Nov. 25, 2025

Why a treatment older than the FDA is getting new regulatory scrutiny

MAHA-aligned patients and providers are pushing back to ensure access to an animal-derived thyroid hormone treatment.

By Kelly Bilodeau • Oct. 20, 2025

Top pharma industry conferences remaining in 2026

Where pharma leaders will converge, discuss and navigate the industry’s shifting landscape in the second half of 2026.

By Meagan Parrish • Updated June 29, 2026

In cell therapy, cost is a hot issue. The industry might need a cold solution.

The logistical linchpin of cryopreservation could make a challenging space more accessible.

By Michael Gibney • Aug. 19, 2025

Despite FDA ruling, compounded GLP-1s are still giving Novo and Lilly headaches on the market

Copycat weight loss drugs were supposed to be pulled from the market, but pharmacies have found a loophole. 

By Amy Baxter • Aug. 18, 2025

Merck KGaA ventures into new territory in the US

How the president of EMD Serono, Merck KGaA, Darmstadt, Germany’s U.S. arm, is leading the charge to “double down” on new innovation.

By Alexandra Pecci • Aug. 15, 2025

Puerto Rico’s ongoing journey from manufacturing hub to innovation enterprise

Biotechs are coming to the island as tariffs threaten overseas drug exports, and finding Puerto Rico is more than just a leading manufacturing hub.  

By Michael Gibney • Aug. 12, 2025

As gene therapies falter on the market, this biopharma is aiming to defy the odds

After a strong launch for its cancer gene therapy, Ferring Pharmaceuticals is setting the stage for long-term growth.

By Meagan Parrish • Aug. 8, 2025

Pharma’s turbo spending spree on US manufacturing

The industry’s push to expand American drug production isn’t abating as threats of tariffs loom.

By Meagan Parrish • July 24, 2025